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IMPORTANCE Increases in prescription opioid use in the United States have been attributed to
changing prescribing guidelines and attitudes toward pain relief; however, the spread of
opioid use within households through drug diversion may also be a contributing factor.
OBJECTIVE To investigate whether individuals living in a household with a prescription opioid
user are more likely to initiate prescription opioids themselves, compared with individuals in
households with a prescription nonsteroidal anti-inflammatory drug (NSAID) user.
DESIGN, SETTING, AND PARTICIPANTS This was a retrospective cohort study using
administrative health care claims data from 2000 to 2014 of commercial insurance
beneficiaries sharing a health plan with continuous prescription drug coverage, without
opioid or NSAID use in the prior year. Enrollees were followed from the date of the first
prescription filled by a household member for an eligible opioid or NSAID until initiation of
prescription opioids, disenrollment, or administrative censoring after 1 year or the end of
follow-up on December 31, 2014. Risk of opioid initiation was derived from inverse
probability-weighted (IPW) Kaplan-Meier estimators that adjusted for potential confounders,
prognostic factors, and predictors of censoring.
EXPOSURE Outpatient pharmacy dispensing of a prescription opioid or prescription NSAID.
MAIN OUTCOMES AND MEASURES Incident outpatient pharmacy fill for a prescription opioid
by a household member.
RESULTS From 2000 to 2014, 12 695 280 individuals were exposed to prescription opioids
and 6 359 639 to prescription NSAIDS through an index prescription to a household member.
The IPW estimated risk of opioid initiation in the subsequent year was 11.83% (95% CI,
11.81%-11.85%) among individuals exposed to prescription opioids in the household,
compared with 11.11% (95% CI, 11.09%-11.14%) among individuals exposed to prescription
NSAIDs, resulting in a risk difference of 0.71% (95% CI, 0.68%-0.74%). An unmeasured
confounder that is modestly associated with the exposure (eg, prevalence difference = 0.9%)
and the outcome (eg, risk difference = 0.9) after adjustment for all measured variables could
explain our observed estimate of the overall risk difference (0.71%).
CONCLUSIONS AND RELEVANCE Living in a household with a prescription opioid user may
increase risk of prescription opioid use, which may reflect both increased access to these
products as well as shared risk factors, such as prescriber preference and prescription drug
monitoring.
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O pioid prescribing in the US increased 300% from1991 to 2009 and totaled 246 million dispensed pre-scriptions in 2015.1-3 Globally, the United States
continues to be the largest consumer of the world’s supply
of hydrocodone (99%) and oxycodone (81%),4 with
hydrocodone-acetaminophen being the leading prescription
drug dispensed by US retail pharmacies.5 This increase in
opioid prescribing has been attributed to changes in pre-
scribing guidelines,6 attitudes toward pain relief,7 aggres-
sive pharmaceutical marketing,8 and the liberalization of
laws governing the ability of physicians to prescribe opioids
without training in pain management.9 Opioid adverse
effects include QT interval prolongation and respiratory
depression, which can lead to opioid-related emergency
department visits,10,11 hospitalizations,12 and death.13 In
2011, prescription opioids were involved in more than
480 000 ER visits and 16 000 deaths, surpassing the mor-
tality burden from firearms and motor vehicle accidents for
Americans ages 35 to 54 years.14 Accidental ingestion of pre-
scription opioids also caused more than 5000 ER visits
among children 5 years or younger in 2011, which under-
scores the harms of the broad availability of opioids in US
households.15
Opioids are often prescribed in doses exceeding clinical
guidelines for patients with non–cancer-related pain,16 and in
large quantities, resulting in surpluses of opioids stored in
household medicine cabinets.17 Unused medications create
opportunities for nonprescribed use and drug sharing among
friends and family members, who may perceive these medi-
cations to be low risk given their storage at home.18 For
example, a third of veterans receiving prescription opioid
therapy report sharing unused medications with family
members,18 and more than 70% of non–medical opioid users
obtain the drugs from family members and friends.19,20
Because prescription medication sharing is common,21 fami-
lies and other social networks likely shape norms and behav-
iors surrounding the use of prescription opioids. Given the
documented spread of substance use behaviors, such as
heavy drinking within social networks,22-25 it is likely that
prescription opioid use can also spread within networks,
such as families. Although a previous study has examined
the association between opioid abuse in one person and opi-
oid abuse in another,26 the extent to which prescribed opioid
use in one person is associated with increased risk of pre-
scribed opioid use in another person remains unknown.
We quantified the association between potential access
to opioids resulting from a new prescription started by a
household member and subsequent new use of prescription
opioids by other family members. Specifically, we compared
the 1-year risk of opioid initiation due to the introduction of
prescription opioids vs introduction of nonopioid analgesics
(prescription nonsteroidal anti-inflammatory drugs
[NSAIDs]) in households of commercial insurance beneficia-
ries that included employees, spouses, and dependents
(hereinafter, opioid households and NSAID households). We
further explored whether associations varied across sub-
groups of age, geographic region, potential indications, refill
availability, days’ supply, and by year and opioid dose.
Methods
We used the 2000-2014 Truven Health Analytics MarketScan
Commercial Claims and Encounters databases covering the
years 2000 to 2014. MarketScan contains standardized, de-
identified, person-level information on enrollment, paid in-
patient and outpatient services and procedures, and outpa-
tient pharmacy dispensing claims of employer-sponsored
commercial insurance beneficiaries, their spouses, and de-
pendents. MarketScan is one of the largest, fully integrated,
and most complete commercial insurance claims databases
available for the United States, where beneficiaries can be
tracked across insurance plans, health care sites, clinician types,
and over time27 with median follow-up of 3 years. The data-
base increased from 3.7 million enrollees to 47.2 million from
2000 to 2014. The Office of Human Research Ethics at the
University of North Carolina at Chapel Hill deemed the study
exempt from review.
Study Population
This retrospective cohort study included household mem-
bers of patients who initiated use of prescription opioids or pre-
scription NSAIDs based on outpatient pharmacy dispensing
claims (henceforth, we refer to the index patient as “Patient
0”). Prescription NSAIDs were chosen as the active compara-
tor group because they have similar indications for treating
pain, which minimizes the potential for unmeasured con-
founding. New use was defined as the first pharmacy dispens-
ing claim after a 365-day period of continuous enrollment with-
out evidence of prescription opioid or prescription NSAID use
in claims. We generalized the “new-user” design28 to “new
households” by requiring all household members to have con-
tinuous prescription drug coverage with no record of prescrip-
tion opioid or NSAID use during the baseline period. House-
hold members entered either the opioid or NSAID cohort at the
index date anchored to the date of initiation by Patient 0. Eli-
gible index dates were those occurring between January 1,
2001, and December 31, 2014, to ensure observation of the
1-year baseline. To make comparisons between cohorts more
rigorous and identify index patients with similar indications,
household members of patients who had a diagnosis of ma-
lignant neoplasm, used hospice services during the baseline
Key Points
Question Is prescription opioid use in one household member
associated with increased risk of prescribed opioid use in other
household members?
Findings In a study comparing 12 695 280 commercial insurance
beneficiaries with a household member who started a new
prescription of opioids, to 6 359 639 beneficiaries with a
household member who started a new prescription of nonopioid
pain relievers, the 1-year risk of subsequent opioid use was 0.71%
higher among individuals exposed to opioids through a household
member’s prescription.
Meaning Prescription opioid use may spread within households.
egorical variable with each year as a separate category. Esti-
mates of precision were obtained using nonparametric boot-
strap resampling with replacement.
We explored potential heterogeneity of the association be-
tween household opioid availability and opioid initiation across
subgroups: age of at-risk household members (0-5, 6-11, 12-
17, 18-25, 26-35, 36-45, 46-55, ≥56 years); region of residence;
potential indication for Patients 0 (back pain [yes vs no]; frac-
ture [yes vs no]; year of cohort entry; and characteristics of the
index prescription (availability of refills [yes vs no]; days of sup-
ply [<30 days or ≥30 days]). Subgroup differences were exam-
ined by stratifying the original cohort and repeating the pri-
mary analysis described herein within each stratum. We further
examined variations in risk by daily opioid dose by convert-
ing all index opioid prescriptions to morphine milligrams
equivalents (MME) and categorized dosage as 0 to 19, 20 to 50,
51 to 89, or 90 or more MME/d.32,33
We performed 2 sensitivity analyses. First, the primary
analysis was performed after restricting to 2-adult (age >18
years) households to account for shared genetic factors that
could give rise to opioid-seeking behavior. Second, we as-
sessed the extent to which unmeasured differences between
the opioid and NSAID cohorts could explain our results.34,35
Additional details are provided in the eMethods in the Supple-
ment. All analyses were conducted using SAS statistical soft-
ware (version 9.4; SAS Institute Inc).
Results
Characteristics of the Study Sample
The study sample comprised 12 695 280 members of 5 871 003
opioid households and 6 359 639 members of 3 015 932 NSAID
households, after excluding 84 810 households (1%) without in-
formation on geographic region (Figure 1). Opioid and NSAID
households were of similar size (median, 3 enrollees; interquar-
tile range [IQR], 2-4 enrollees), but opioid households were more
likely to reside in the South than NSAID households (Table 1).
Demographic characteristics were similar between cohorts: the
median age of household members was 22 years (IQR, 11-45
years), and less than half were female. Overall, baseline cova-
riates were balanced between household exposure groups. How-
ever, compared with members of NSAID households, slightly
greater proportions of members of opioid households had used
attention-deficit/hyperactivity disorder medications, antibiot-
ics, benzodiazepines, selective serotonin reuptake inhibitors
(SSRIs), and sleep medications, but not β-blockers, statins, or
muscle relaxants during baseline. Members of opioid house-
holds were also more likely than members of NSAID households
to have a history of back and neck pain, migraine, fractures, de-
pression, substance abuse, and cancer screening, and less likely
to have diabetes mellitus and arthritis. However, utilization of
outpatient and inpatient services and emergency department
visits were similar between household exposure groups.
Unadjusted Analysis
Members of opioid households and NSAID households were
followed for a median of 1 year (IQR, 0.6-1.0-year). During
period, or initiated both prescription opioids and NSAIDs on 
the same day were excluded.
Opioid Medication Exposure
Pharmacy dispensing billing claims for the most commonly pre-
scribed synthetic and semisynthetic opioids and NSAIDs were 
identified in the Outpatient Pharmaceutical Claims file by their 
generic string name. Opioids and NSAIDs were restricted to oral 
and transdermal formulations (see eTable 1 in the Supple-
ment). We excluded claims for opioids used primarily to treat 
Parkinson disease (apomorphine), opioid dependence (metha-
done), and cough (potassium guaiacolsulfonate–hydroco-
done bitartrate).
Outcome Assessment
Our primary outcome was initiation of prescription opioids by 
members of the index patient’s household. Initiation by a house-
hold member was assessed similarly to cohort eligibility defined 
by Patient 0 using the dispensing date for an eligible opioid in 
the Outpatient Pharmaceutical claims database.
Covariates
Baseline covariates for household members were assessed dur-
ing the year prior to the index date defined by Patient 0. Po-
tential confounders of the association between opioid re-
ceipt in Patient 0 and opioid initiation by household members 
were identified a priori using subject matter knowledge and 
causal diagrams,29 and included household size, composi-
tion (children <18 years, yes/no), region of residence (North-
east, North Central, South, West), calendar year of cohort en-
try, and history of substance use diagnosis for Patient 0 (yes/
no). Baseline predictors of loss to follow-up (defined as 
disenrollment) and opioid initiation of at-risk household mem-
bers included age, sex, history of chronic pain diagnosis, psy-
chiatric comorbidity (dichotomous variables for yes/no), health 
care utilization (number of outpatient visits, continuous; emer-
gency department visit in prior 7 or 30 days, yes/no), and use 
of scheduled prescription medications (dichotomous vari-
ables for yes/no for each drug class; see eTable 1 in the 
Supplement for definitions).
Statistical Analyses
We estimated the 1-year risk of opioid initiation by household 
members (excluding Patients 0) within each treatment group 
using the complement of the Kaplan-Meier estimator with time 
in days from the index date. Household members were indi-
vidually censored at the earliest of an event, at 1 year of follow-
up, disenrollment, or administrative censoring on December 
31, 2014.
We estimated 1-year risks and risk differences (RDs) for opi-
oid initiation using inverse probability-weighted Kaplan-
Meier estimators adjusting for baseline confounders, prog-
nostic factors, and dropout.30 Weights were the product of 
inverse probability of treatment and inverse probability of cen-
soring weights (see the eMethods in the Supplement for de-
tails on the construction of weights). Age, number of outpa-
tient visits during baseline, and household size were modeled 
using restricted quadratic splines31 and calendar year as a cat-
eprinted)
14 846 450 person-years of follow-up, 1 786 014 individuals ini-
tiated use of prescription opioids and 4 187 048 individuals dis-
enrolled from their health plan (21% in NSAID households, 22%
in opioid households). Overall, the 1-year risk of prescription
opioid initiation by a second household member was 11.32%
(95% CI, 11.30%-11.34%). The 1-year unadjusted risk of pre-
scription opioid initiation was 11.68% (95% CI, 11.66%-
11.70%) within opioid households and 10.60% (95% CI, 10.57%-
10.63%) within NSAID households.
Inverse Probability-Weighted Analysis
All potential confounders and predictors of opioid initiation
or dropout identified a priori were included in corresponding
propensity score models for treatment and censoring weights.
The means of the treatment and censoring weights were 1.00
(range, 0.36-6.06) and 0.98 (range, 0.36-3.59), respectively. Cu-
mulative incidence curves for opioid initiation over 1 year of
follow-up by household opioid availability are presented in
Figure 2. The 1-year risk of opioid initiation was 11.83% (95%
CI, 11.81%-11.85%) among individuals in an opioid house-
hold, compared with 11.11% (95% CI, 11.09%-11.14%) among
Figure 1. Derivation of Cohort in the MarketScan Commercial Claims and
Encounters Databases, 2000-2014
274 882 Excluded
History of malignant neoplasm or hospice
202 531 Opioid group
72 351 NSAID group
6 060 996 Excluded
Singly enrolled initiators
3 903 793 Opioid group
2 157 203 NSAID group
Patients initiating monotherapy with prescription opioid or prescription
NSAID, 2001-2014, with continuous insurance enrollment and
prescription drug coverage in 1 year prior to initiation
15 394 598 Opioid group
7 925 687 NSAID group
Patients without history of malignant neoplasm or hospice care in prior year
15 192 067 Opioid group
7 853 336 NSAID group
Patients enrolled on health plan with ≥1 other person
11 288 274 Opioid group
5 696 133 NSAID group
Members of households
12 812 496 Opioid group
6 427 670 NSAID group
Households without opioid/NSAID prescription in prior year
5 871 003 Opioid group
3 015 932 NSAID group
8 097 472 Excluded
Prevalent household use of opioids:
4 455 482 Opioid group
2 045 098 NSAID group
Prevalent household use of Rx NSAIDs:
2 923 069 Opioid group
1 649 010 NSAID group
Prevalent household use of both Rx:
1 931 689 Opioid group
995 545 NSAID group
NSAID indicates nonsteroidal anti-inflammatory drug; Rx, prescription.
Table 1. Baseline Characteristics of Household Members
of Prescription Analgesic Initiators, MarketScan Commercial
Claims and Encounters, 2000-2014a
Characteristic
Opioid Households
(n = 12 695 280)
NSAID Households
(n = 6 359 639)
Demographics
Female sex 48.5 48.1












ADHD medications 1.5 1.4
Antibiotics 36.0 35.8
Muscle relaxants 1.0 1.0




Back and neck pain 7.6 7.0
Back pain 3.7 3.5










Substance abuse 1.0 1.0
Alcohol use 0.3 0.3
Gastrointestinal bleeding 0.5 0.5
COPD 0.4 0.4
Health care utilization
ER visit in past 30 d 1.1 1.1
ER visit in past 7 d 0.4 0.3
Outpatient visits, mean (SD) 2.3 (2.95) 2.4 (3.03)
Inpatient days, mean (SD) 0.1 (1.40) 0.1 (1.42)
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; COPD, chronic
obstructive pulmonary disease; ER, emergency department; IQR, interquartile
range; SSRIs, selective serotonin reuptake inhibitors.
a Data are given as percentages except where noted. Covariates are defined in
eTable 1 in the Supplement. Baseline characteristics were assessed in the 1 y
prior to the index date.
Sensitivity Analyses
In 2-adult households (n = 2 706 922), an opioid prescription
to 1 adult was associated with increased risk of opioid initia-
tion in the other (RD, 1.08% [95% CI, 0.90%-1.39%]). Al-
though we controlled for a number of potential confounders,
we also assessed the sensitivity of our findings to unmea-
sured baseline differences between the opioid and NSAID
groups (eTable 2 in the Supplement). We found that an un-
measured confounder that is modestly associated with the ex-
posure (eg, prevalence difference = 0.9%) and the outcome
(eg, RD = 0.9) after adjustment for all measured variables could
explain our observed estimate of the RD (0.71%). Alternative
scenarios are presented in eTable 2 in the Supplement.
Discussion
We conducted a large, retrospective, cohort study comparing
the risk of opioid initiation among commercial insurance ben-
eficiaries who were newly exposed to prescription opioids vs
prescription NSAIDs through a household member’s prescrip-
tion. We observed a 0.71% absolute higher 1-year risk of pre-
scription opioid use among individuals in opioid households
compared with prescription NSAID households, which could
reflect increased access to these products or unmeasured risk
factors. Associations varied across age, region, potential indi-
cation, and characteristics of the index prescription.
Previous studies on prescription opioids have used
MarketScan,36-39 but none examined patterns of use within
families. Prior research within families focused on disentan-
gling genetic vs environmental transmission of drug abuse25;
however, opiate abuse can develop from opioids prescribed for
pain management.40 Because medication sharing cannot be
captured in administrative data, understanding patterns of pre-
scribed opioid use within households may be a critical first step
toward addressing the opioid epidemic. If associations across
households and social networks are validated in future stud-
ies, even small risk differences may be relevant on a popula-
tion level, considering the broad environmental availability of
prescription opioids.
We assessed whether our results could be explained by po-
tential unmeasured differences between members of opioid
and NSAID households in sensitivity analyses. Unmeasured
variables include whether household members see the same
health care professional with a preference for prescribing opi-
oids. We found that the magnitude of such an effect need not
be large to explain our findings. A previous study estimated
physician preference for prescribing the same analgesic to be
more than 20%41; thus, it is plausible that our results could be
explained by unmeasured health care professional prefer-
ence if household members see the same provider (eg, physi-
cian, dentist). Alternatively, unmeasured environmental or sys-
tem-level factors or household socioeconomic status may have
given rise to confounding.34
The association between potential access to household opi-
oids and opioid initiation could be explained by multiple
mechanisms. First, family members may share their medica-
tions with other members, which may lead to one seeking his
Figure 2. Inverse Probability-Weighted Cumulative Incidence Curves
for Opioid Initiation by Household Availability of Prescription Opioids,
































Estimates adjusted for household size, region, year of cohort entry, family
history of substance abuse, age, sex, baseline pain and psychiatric
co-morbidities, use of scheduled and unscheduled prescription medications,
and health care utilization. NSAID indicates nonsteroidal anti-inflammatory
drug.
individuals in an NSAID household (Table 2). The adjusted 
1-year RD in opioid initiation due to potential access to house-
hold opioids was 0.71% (95% CI, 0.68%-0.74%).
Subgroup Analyses
The association between household opioid availability and opi-
oid initiation varied across subgroups of age, geographic re-
gion, and potential indication of Patient 0 (Table 2). The RD 
among younger adults ages 18 to 25 years was 0.91% (95% CI, 
0.81%-1.01%), compared with 1.26% (95% CI, 1.08%-1.43%) 
among those ages 26 to 35 years. In the North Central region, 
the RD was 0.44% (95% CI, 0.38%-0.51%), compared with 
0.95% (95% CI, 0.88%-1.02%) in the West. Risk differences did 
not vary by history of back and neck pain in Patient 0, but RDs 
were markedly smaller among household members of 
patients with a history of fracture (RD, 0.42% [95% CI, 0.21%-
0.61%]) than those without (RD, 0.82% [95% CI, 0.79%-
0.85%]).
Results varied across characteristics of the index prescrip-
tion (Table 3). The RD for opioid initiation was 0.53% (95%
CI, 0.49%-0.57%) in households where the index supply was 
less than 30 days, compared with 1.14% (95% CI, 0.97%-
1.34%) in households with at least a 30-day supply. The RD was 
0.44% (95% CI, 0.40%-0.47%) in households with a single fill 
of the index prescription, compared with 1.43% (95% CI, 1.33%-
1.53%) in households with refills. Compared with NSAID house-
holds, the RD for opioid initiation in households with an in-
dex opioid prescription for less than 20 MME/d was 1.44% (95%
CI, 1.39%-1.50%), 0.81% (95% CI, 0.77%-0.85%) for 20-50 
MME/d, 0.78% (95% CI, 0.72%-0.83%) for 51-89 MME/d, and 
1.02% (95% CI, 0.95%-1.07%) for ≥90 MME/d. Risk differ-
ences did not vary appreciably over the years of the study (see 
eFigures 1 and 2 in the Supplement).
 (Reprinted)
or her own prescription. Second, household opioid use may
shape attitudes and norms of opioid use.26 Third, spousal cor-
respondence of opioid use may be due to homophily, which
is defined as the inclination of similar individuals to associate.42
Although we could not disentangle potential mechanisms, in-
terventions that address the opioid epidemic could include ini-
tiatives promoting safe medication storage within house-
holds and safe disposal of unused medications. Clinicians may
need to consider the context within which medications will
be used to assess the risks and benefits of prescribing opi-
oids. For certain patients, prescribing in smaller quantities or
without refills may help mitigate the risk of subsequent opi-
oid use by a household member.
Strengths and Limitations
We generalized the “new-user” design28 to leverage informa-
tion on households in large administrative databases and re-
strict to enrollees who had no prior access to opioids or NSAIDs
in the household. The benefit of our “new-household” ap-
proach is the exclusion of households with prevalent use of
Table 2. Cumulative Incidence of Opioid Initiation Among Household Members of Prescription Opioid
vs Prescription NSAID Initiators Overall and by Age, Region, and Potential Indication for Opioid Initiation
by Patient 0, MarketScan Commercial Claims and Encounters, 2000-2014
Opioid
Initiation








11.83 (11.81-11.85) 11.11 (11.09-11.14) 0.71 (0.68-0.74) 1.06 (1.06-1.07)
Subgroup analyses
Age group, y
0-5 3.6 (3.5-3.6) 3.2 (3.1-3.2) 0.41 (0.35-0.48) 1.13 (1.11-1.15)
6-11 3.7 (3.7-3.8) 3.3 (3.3-3.4) 0.41 (0.36-0.45) 1.12 (1.11-1.14)
12-17 10.2 (10.2-10.3) 9.5 (9.4-9.5) 0.77 (0.70-0.86) 1.08 (1.07-1.09)
18-25 13.7 (13.6-13.7) 12.8 (12.7-12.8) 0.91 (0.81-1.01) 1.07 (1.06-1.08)
26-35 18.8 (18.7-18.9) 17.5 (17.4-17.7) 1.26 (1.08-1.43) 1.07 (1.06-1.08)
36-45 16.0 (16.0-16.1) 15.3 (15.2-15.4) 0.72 (0.62-0.80) 1.05 (1.04-1.05)
46-55 15.7 (15.6-15.7) 15.1 (15.0-15.1) 0.62 (0.52-0.71) 1.04 (1.03-1.05)
≥56 17.1 (17.0-17.2) 16.3 (16.1-16.4) 0.85 (0.73-1.00) 1.05 (1.04-1.06)
Region
Northeast 9.6 (9.6-9.7) 9.1 (9.0-9.1) 0.57 (0.47-0.66) 1.12 (1.11-1.14)
North
Central
11.5 (11.4-11.5) 11.0 (11.0-11.1) 0.44 (0.38-0.51) 1.08 (1.07-1.09)
South 13.2 (13.1-13.2) 12.4 (12.3-12.4) 0.76 (0.71-0.81) 1.07 (1.06-1.08)





12.1 (12.0-12.1) 11.3 (11.3-11.4) 0.78 (0.71-0.85) 1.07 (1.06-1.08)
No back and
neck pain
11.8 (11.8-11.8) 11.0 (11.0-11.0) 0.81 (0.77-0.84) 1.07 (1.07-1.08)
Fracture 12.1 (12.0-12.2) 11.7 (11.5-11.9) 0.42 (0.21-0.61) 1.04 (1.02-1.05)




17.7 (17.6-17.9) 16.6 (16.5-16.8) 1.08 (0.90-1.32) 1.06 (1.05-1.08)
Abbreviation: NSAID, nonsteroidal
anti-inflammatory drugs.
a Risks, risk differences, and risk
ratios adjusted for household size,
household composition, year of
cohort entry, region and/or age, sex,
family history of substance abuse,
pain and psychiatric comorbidities,
use of scheduled and unscheduled
prescription medications, and
health care utilization.
b For risk difference homogeneity,
P < .001 for all comparisons.
c Households with 2 adults older than
18 y.
Table 3. Cumulative Incidence of Opioid Initiation Among Household Members of Prescription Opioid





1-y Risk, % (95% CI)a
NSAID Household,





Overall 11.8 (11.8-11.8) 11.1 (11.1-11.1) 0.71 (0.68-0.74) 1.06 (1.06-1.07)
Supply, d
<30 12.0 (12.0-12.0) 11.5 (12.0-11.5) 0.53 (0.49-0.57) 1.05 (1.04-1.05)
≥30b 12.8 (12.7-13.0) 11.7 (13.0-11.8) 1.14 (0.97-1.34) 1.10 (1.08-1.11)
Refills
No 11.8 (11.8-11.9) 11.4 (11.9-11.4) 0.44 (0.40-0.47) 1.04 (1.03-1.04)
Yesb 13.5 (13.5-13.6) 12.1 (13.6-12.2) 1.43 (1.33-1.53) 1.12 (1.11-1.13)
Abbreviation: NSAID, nonsteroidal
anti-inflammatory drugs.
a Risks, risk differences, and risk
ratios adjusted for household size,
household composition, year of
cohort entry, region and/or age, sex,
family history of substance abuse,
pain and psychiatric comorbidities,
use of scheduled and unscheduled
prescription medications, and
health care utilization.
b For RD homogeneity, P < .001 for all
comparisons.
bursement is based on complete and accurate claims.44 Al-
though opioids paid for in cash or received in inpatient set-
tings were not captured in our data, approximately 15% of
opioid prescriptions in 2008 were paid for in cash45 and 90%
of opioids are dispensed from retail pharmacies.46 Similarly,
pharmacy dispensing billing claims were used to identify pre-
scription NSAIDs. Although we expect the sensitivity of pre-
scription NSAID exposure to be high, we lack information on
over-the-counter (OTC) NSAID use. However, OTC NSAID ex-
posure is not expected to be a substantial source of bias in our
study because sensitivity analyses have shown that prescrip-
tion claims data can provide valid estimates of drug-outcome
associations even when a large proportion of drug use is OTC.47
Conclusions
Although we cannot rule out shared risk factors, such as cli-
nician preference, prescription drug monitoring, or genetic pre-
dilection, our results suggest that opioid prescribing deci-
sions may need to take into account the context within which
medications will be used and the potential risk of subsequent
opioid initiation by other individuals. Addressing the opioid
use epidemic will require comprehensive solutions for all as-
pects contributing to this public health issue, including the po-
tential for medication sharing and other unintended conse-
quences of prescription opioid use in households.
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